AF9 anticorps (C-Term)

N° du produit ABIN390128

Détail du produit anti-AF9 anticorps

Antigène: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Épitope: AA 471-502, C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp AF9 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Homologie: M

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogène: This AF9 (MLLT3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 471-502 amino acids from the C-terminal region of human AF9 (MLLT3).

Clone: RB2249-2250

Isotype: Ig Fraction

Information d'application

Indications d'application: WB: 1:1000. IHC-P: 1:50~100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Date de péremption: 6 months

Références pour anticorps anti-AF9 (ABIN390128)

Benedikt, Baltruschat, Scholz, Bursen, Arrey, Meyer, Varagnolo, Müller, Karas, Dingermann, Marschalek: "The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures." dans: Leukemia, Vol. 25, Issue 1, pp. 135-44, (2011) (PubMed).

Bitoun, Oliver, Davies: "The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling." dans: Human molecular genetics, Vol. 16, Issue 1, pp. 92-106, (2007) (PubMed).

Détails sur AF9

Antigène: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Autre désignation: AF9 (MLLT3) (MLLT3 Produits)

Synonymes: anticorps fc39c11, anticorps wu:fc39c11, anticorps zgc:110210, anticorps AF9, anticorps YEATS3, anticorps 2210011H10Rik, anticorps 2610012I03Rik, anticorps 3830408D16Rik, anticorps Af9, anticorps D4Ertd321e, anticorps Af-9, anticorps MLLT3, super elongation complex subunit, anticorps myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3, anticorps mllt3, anticorps MLLT3, anticorps Mllt3

Sujet: The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.

Poids moléculaire: 63351

ID gène: 4300

NCBI Accession: NP_004520

UniProt: P42568